Laura A. Huppert

2 months ago | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences. Video content above is prompted by the following:Briefly discuss how you approach treatment for patients with HER2-ultralow metastatic breast cancer.

2 months ago | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations. Video content above is prompted by the following:Please discuss the recent findings from the DESTINY-Breast06 trial, highlighting key efficacy and safety findings and their implications for the treatment of HER2-low/ultralow metastatic breast cancer.

Jan 22, 2025 | onclive.com | Neil M. Iyengar |Sara A. Hurvitz |Laura A. Huppert |Melinda L. Telli

OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates. Video content above is prompted by the following:Provide a brief overview of the treatment landscape for HER2-low advanced breast cancer.

Aug 17, 2024 | targetedonc.com | Laura A. Huppert

A real-world retrospective study examined how 2 drugs, trastuzumab deruxtecan (T-DXd; Enhertu) and sacituzumab govitecan (SG; Trodelvy), work when used one after the other in patients with HER2-low metastatic breast cancer. Researchers looked at patient data to see how long patients lived without their cancer progressing and how long they lived overall.

Jul 18, 2024 | targetedonc.com | Aditya Bardia |Laura A. Huppert

July 18, 2024By Laura Huppert, MD, and Aditya Bardia, MD, MPH, FASCO, provide closing thoughts on the evolving treatment landscape for HER-negative and HER2-low metastatic breast cancer. Video content above is prompted by the following question:What do you envision for the role of ADCs in the future treatment of HER-negative and HER2-low metastatic breast cancer? Related Content Related Content